<s>
PI-RADS	B-Algorithm
is	O
an	O
acronym	O
for	O
Prostate	O
Imaging	O
Reporting	O
and	O
Data	O
System	O
,	O
defining	O
standards	O
of	O
high	O
quality	O
clinical	O
service	O
for	O
multi-parametric	O
Magnetic	O
Resonance	O
Imaging	O
(	O
mpMRI	O
)	O
,	O
including	O
image	O
creation	O
and	O
reporting	O
.	O
</s>
<s>
Dr.	O
Jelle	O
Barentsz	O
published	O
with	O
the	O
ESUR	O
Prostate	O
MRI	O
Committee	O
the	O
first	O
PI-RADS	B-Algorithm
(	O
v.1	O
)	O
version	O
in	O
December	O
2011	O
.	O
</s>
<s>
Following	O
this	O
initiative	O
the	O
ACR	O
,	O
ESUR	O
,	O
and	O
the	O
AdMeTech	O
Foundation	O
formed	O
a	O
Joint	O
Steering	O
Committee	O
,	O
and	O
by	O
2016	O
published	O
a	O
second	O
version	O
of	O
PI-RADS	B-Algorithm
(	O
v.2	O
)	O
in	O
European	O
Urology	O
.	O
</s>
<s>
In	O
2019	O
the	O
PI-RADS	B-Algorithm
Steering	O
Committee	O
published	O
an	O
updated	O
version	O
:	O
PI-RADS	B-Algorithm
v2.1	O
.	O
</s>
<s>
Prostate	O
MRI	O
using	O
PI-RADS	B-Algorithm
to	O
detect	O
clinically	O
significant	O
cancer	O
is	O
now	O
widely	O
by	O
European	O
urologists	O
,	O
as	O
is	O
illustrated	O
with	O
the	O
'	O
2020	O
EAU	O
Innovators	O
in	O
Urology	O
Award	O
 '	O
for	O
Dr.	O
Barentsz	O
.	O
</s>
<s>
The	O
aim	O
of	O
prostate	O
MRI	O
using	O
PI-RADS	B-Algorithm
is	O
to	O
assess	O
the	O
risk	O
of	O
clinically	O
significant	O
prostate	O
cancer	O
being	O
present	O
.	O
</s>
<s>
Furthermore	O
,	O
the	O
PI-RADS	B-Algorithm
v2	O
system	O
is	O
designed	O
to	O
standardize	O
prostate	O
MRI	O
.	O
</s>
<s>
Various	O
studies	O
have	O
compared	O
the	O
predictive	O
performance	O
of	O
PI-RADS	B-Algorithm
v1	O
for	O
detecting	O
significant	O
prostate	O
cancer	O
against	O
either	O
image-guided	O
biopsy	O
results	O
(	O
definitive	O
pathology	O
)	O
and/or	O
prostatectomy	O
specimens	O
(	O
histopathology	O
)	O
.	O
</s>
<s>
In	O
a	O
2015	O
articles	O
in	O
the	O
Journal	O
of	O
Urology	O
,	O
Thompson	O
reported	O
multi-parametric	O
MRI	O
detection	O
of	O
significant	O
prostate	O
cancer	O
had	O
sensitivity	O
of	O
96%	O
,	O
specificity	O
of	O
36%	O
,	O
negative	O
predictive	O
value	O
and	O
positive	O
predictive	O
values	O
of	O
92%	O
and	O
52%	O
;	O
when	O
PI-RADS	B-Algorithm
was	O
incorporated	O
into	O
a	O
multivariate	O
analysis	O
(	O
PSA	O
,	O
digital	O
rectal	O
exam	O
,	O
prostate	O
volume	O
,	O
patient	O
age	O
)	O
the	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
improved	O
from	O
0.776	O
to	O
0.879	O
,	O
p	O
<	O
0.001	O
.	O
</s>
<s>
A	O
similar	O
paper	O
in	O
European	O
Radiology	O
found	O
that	O
when	O
correlated	O
with	O
histopathology	O
,	O
PI-RADS	B-Algorithm
v2	O
correctly	O
identified	O
94-95	O
%	O
of	O
prostate	O
cancer	O
foci	O
≥	O
0.5	O
mL	O
,	O
but	O
was	O
limited	O
for	O
the	O
assessment	O
of	O
GS	O
≥4+3	O
(	O
significant	O
)	O
tumors	O
≤	O
0.5	O
mL	O
;	O
in	O
their	O
series	O
,	O
DCE-MRI	O
offered	O
limited	O
added	O
value	O
to	O
T2WI+	O
DW-MRI	O
.	O
</s>
<s>
Other	O
applications	O
for	O
which	O
PI-RADS	B-Algorithm
may	O
be	O
useful	O
include	O
prediction	O
of	O
termination	O
of	O
Active	O
Surveillance	O
due	O
to	O
tumor	O
progression/aggressiveness	O
,	O
detection	O
of	O
extraprostatic	O
extension	O
of	O
prostate	O
cancer	O
,	O
and	O
supplemental	O
information	O
when	O
considering	O
whether	O
to	O
re-biopsy	O
patients	O
with	O
a	O
history	O
of	O
previous	O
negative	O
biopsy	O
.	O
</s>
<s>
PI-RADS	B-Algorithm
v2	O
is	O
designed	O
to	O
improve	O
detection	O
,	O
characterization	O
and	O
risk	O
stratification	O
in	O
patients	O
suspected	O
of	O
prostate	O
cancer	O
with	O
a	O
goal	O
of	O
better	O
treatment	O
decisions	O
,	O
improved	O
outcomes	O
and	O
simplified	O
reporting	O
.	O
</s>
